Parametric Portfolio Associates LLC increased its position in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 0.2% during the second quarter, Holdings Channel reports. The fund owned 354,011 shares of the biopharmaceutical company’s stock after purchasing an additional 682 shares during the quarter. Parametric Portfolio Associates LLC’s holdings in Alexion Pharmaceuticals were worth $46,368,000 as of its most recent filing with the Securities & Exchange Commission.
Other hedge funds have also recently added to or reduced their stakes in the company. CIBC Asset Management Inc grew its position in Alexion Pharmaceuticals by 14.1% in the 2nd quarter. CIBC Asset Management Inc now owns 60,702 shares of the biopharmaceutical company’s stock valued at $7,951,000 after buying an additional 7,484 shares in the last quarter. FMR LLC grew its position in Alexion Pharmaceuticals by 10.4% in the 1st quarter. FMR LLC now owns 29,144,320 shares of the biopharmaceutical company’s stock valued at $3,939,729,000 after buying an additional 2,746,055 shares in the last quarter. Origin Asset Management LLP grew its position in Alexion Pharmaceuticals by 22.3% in the 1st quarter. Origin Asset Management LLP now owns 105,200 shares of the biopharmaceutical company’s stock valued at $14,221,000 after buying an additional 19,200 shares in the last quarter. GAM Holding AG grew its position in Alexion Pharmaceuticals by 27.4% in the 1st quarter. GAM Holding AG now owns 41,160 shares of the biopharmaceutical company’s stock valued at $5,564,000 after buying an additional 8,858 shares in the last quarter. Finally, Rehmann Capital Advisory Group grew its position in Alexion Pharmaceuticals by 34.5% in the 1st quarter. Rehmann Capital Advisory Group now owns 2,293 shares of the biopharmaceutical company’s stock valued at $310,000 after buying an additional 588 shares in the last quarter. 93.23% of the stock is currently owned by institutional investors and hedge funds.
In other Alexion Pharmaceuticals news, EVP Indrani Lall Franchini sold 4,500 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $132.78, for a total value of $597,510.00. Following the completion of the transaction, the executive vice president now directly owns 29,627 shares in the company, valued at $3,933,873.06. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Aradhana Sarin sold 578 shares of the firm’s stock in a transaction dated Friday, June 21st. The stock was sold at an average price of $132.00, for a total transaction of $76,296.00. Following the completion of the transaction, the insider now owns 30,201 shares of the company’s stock, valued at $3,986,532. The disclosure for this sale can be found here. Company insiders own 4.08% of the company’s stock.
Shares of NASDAQ:ALXN traded down $0.86 during trading hours on Friday, hitting $107.40. 1,087,405 shares of the company’s stock traded hands, compared to its average volume of 3,195,241. Alexion Pharmaceuticals, Inc. has a 52 week low of $92.56 and a 52 week high of $141.86. The company has a debt-to-equity ratio of 0.26, a quick ratio of 3.56 and a current ratio of 4.04. The company’s fifty day simple moving average is $109.85 and its two-hundred day simple moving average is $124.51. The company has a market cap of $24.27 billion, a price-to-earnings ratio of 15.15, a price-to-earnings-growth ratio of 1.03 and a beta of 1.67.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Wednesday, July 24th. The biopharmaceutical company reported $2.64 EPS for the quarter, topping the consensus estimate of $2.13 by $0.51. Alexion Pharmaceuticals had a net margin of 29.64% and a return on equity of 20.23%. The company had revenue of $1.20 billion during the quarter, compared to analysts’ expectations of $1.18 billion. During the same period last year, the company posted $2.07 earnings per share. The business’s revenue for the quarter was up 15.1% on a year-over-year basis. On average, analysts anticipate that Alexion Pharmaceuticals, Inc. will post 9.03 EPS for the current fiscal year.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and Soliris (eculizumab), a monoclonal antibody for the treatment of PNH, atypical hemolytic uremic syndrome (aHUS), and generalized myasthenia gravis.
Featured Article: How do CD ladders protect against rising interest rates?
Want to see what other hedge funds are holding ALXN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.